Compared with placebo , adjunctive aripiprazole increased the likelihood of response in all subgroups ( risk ratio -LSB- @ % CI -RSB- : mild , @ -LSB- @ , @ -RSB- ; moderate , @ -LSB- @ , @ -RSB- ; severe , @ -LSB- @ , @ -RSB- ) .